HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kostakoglu, L. Articles by Goldsmith, S. J. Search for Related Content PubMed PubMed Citation Articles by Kostakoglu, L. Articles by Goldsmith, S. J.

PET in the Assessment of Therapy Response in Patients with Carcinoma of the Head and Neck and of the Esophagus*

Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Medical College, Cornell University, New York, New York

In patients with carcinoma of the head and neck and of the esophagus, metabolic and functional imaging by PET with ¹⁸F-FDG has a pivotal role in the evaluation of tumor response to therapy, specifically, in the prediction of progression-free survival and overall survival. Metabolic imaging allows the detection of biochemical changes within tumor cells as opposed to identifiable morphologic changes. Anatomic imaging modalities do not reliably differentiate between responders and nonresponders early during the course of follow-up. The correlation between histopathologic tumor response after preoperative therapy and clinical prognosis is well established for many cancers. Squamous carcinoma of the head and neck and esophageal carcinoma demonstrate avid ¹⁸F-FDG uptake. For these cancers, ¹⁸F-FDG PET parallels histopathologic findings in its ability to detect residual viable tumor; therefore, it is a valuable tool for the noninvasive assessment of histopathologic tumor response in advanced-stage cases after neoadjuvant therapy before surgery. Early determination of nonresponders is of prime importance, as timely therapy modification can be accomplished for patients who do not demonstrate a response to therapy. This determination is exceptionally important for head and neck and esophageal malignancies, both of which are known for their unfavorable prognosis, as early modifications in therapy regimens for nonresponders may improve patient outcome. There is now evidence that ¹⁸F-FDG PET is a sensitive and specific method for determining therapy response and for providing important prognostic information for these cancers. Therefore, ¹⁸F-FDG PET may change patient management and lead to improved survival for a selected group of patients with carcinoma of the head and neck and of the esophagus.

Key Words: oncology • PET • PET/CT • ¹⁸F-FDG PET • esophageal carcinoma • head and neck carcinoma • response to therapy

This article has been cited by other articles:

				H. Igaki, K. Nakagawa, K. Shiraishi, S. Shiina, N. Kokudo, A. Terahara, H. Yamashita, N. Sasano, M. Omata, and K. Ohtomo Three-dimensional Conformal Radiotherapy for Hepatocellular Carcinoma with Inferior Vena Cava Invasion Jpn. J. Clin. Oncol., June 1, 2008; 38(6): 438 - 444. [Abstract] [Full Text] [PDF]

				J.M. Debnam, A.S. Garden, and L.E. Ginsberg Benign Ulceration as a Manifestation of Soft Tissue Radiation Necrosis: Imaging Findings AJNR Am. J. Neuroradiol., March 1, 2008; 29(3): 558 - 562. [Abstract] [Full Text] [PDF]

				H. Lau, T. Phan, J. MacKinnon, and T. W. Matthews Absence of Planned Neck Dissection for the N2-N3 Neck After Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Arch Otolaryngol Head Neck Surg, March 1, 2008; 134(3): 257 - 261. [Abstract] [Full Text] [PDF]

				M. Kawashima, H. Fujii, R. Hayashi, M. Tahara, K. Nasu, S. Arahira, and T. Ogino Influence of Delayed Tumor Clearance on Reliability of Complete Response Rate in Chemoradiotherapy for Head and Neck Cancer Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym072v1. [Abstract] [Full Text] [PDF]

				W. A. Weber Use of PET for Monitoring Cancer Therapy and for Predicting Outcome J. Nucl. Med., June 1, 2005; 46(6): 983 - 995. [Abstract] [Full Text] [PDF]

				V. Kapoor, M. B. Fukui, and B. M. McCook Role of 18FFDG PET/CT in the Treatment of Head and Neck Cancers: Posttherapy Evaluation and Pitfalls Am. J. Roentgenol., February 1, 2005; 184(2): 589 - 597. [Full Text] [PDF]

				J. H. Thrall Personalized Medicine Radiology, June 1, 2004; 231(3): 613 - 616. [Full Text] [PDF]